Imatinib represents the first in a class of drugs targeted against chronic myelogenous leukemia to enter the clinic, showing excellent efficacy and specificity for Abl, Kit, and PDGFR kinases. This evidence concerns the gene PDGFRB and chronic myelogenous leukemia, BCR-ABL1 positive.